1. Scrip
  2. >>R&D

Sana Lifted By Allo-CAR-T Data, Moves Ahead Into Autoimmune Disease

 
• By Andrew McConaghie

Sana claims to has cracked one of allo-CAR-Ts biggest challenges, blocking NK cells from destroying the therapies, and for now, investors are impressed.

Sana

Sana has won over investors with new early data from its off-the-shelf CAR-T candidate, SC291, the results suggesting its ‘hypoimmune modified’ design might overcome some of field’s long-standing obstacles.

Key Takeaways

  • Hopes of a breakthrough in allo-CAR-Ts have been dashed repeatedly, but Sana thinks its Phase I results are significant

The initial results from the Phase I ARDENT trial concern six patients with a variety of different lymphomas. Three out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.